All News

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 billion investment to strengthen U.S. pharmaceutical distribution, and new industry collaborations advancing autoimmune and oncology research pipelines.

Following Pfizer's lawsuits, Novo Nordisk enhanced its acquisition offer for Metsera, resulting in Pfizer also sending an enhanced offer.

Boehringer Ingelheim and Merck focus on innovative biologic and oncology advancements, driving collaborative growth through new R&D funding, and development and commercialization agreements.

Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.

The third entry in our premium webinar series dives into the implications the MFN order might have on wider market.

Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI’s full potential in pharma.

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged intellectual property infringement, Eli Lilly’s $3 billion investment in a new Netherlands manufacturing site, and the latest wave of biotech partnerships and licensing agreements driving innovation.

Part three of our three-part webinar series airs live tonight at 7 p.m. ET, unpacking how most favored nation pricing, import tariffs and direct-to-consumer channels could ripple through payer contracts, 340B and practice economics.

FDA's approval of Kygevvi as the first treatment for thymidine kinase 2 deficiency offers hope to patients and families affected by this rare disease.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Raj Indupuri, CEO, eClinical Solutions,pharma’s biggest AI adoption hurdles lie in scaling beyond pilots, ensuring data security, and building user trust within a regulated environment.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s plan to submit its oral GLP-1 candidate for FDA priority review, the departure of senior FDA official George Tidmarsh, and growing global venture capital investment in biopharma innovation.

The personal care corporation will add Tylenol to its portfolio, along with the rest of Kenvue’s brands.

Pfizer's lawsuits come after Novo Nordisk proposed an unsolicited acquisition proposal to Metsera.

There are conflicting reports as to the cause, although it appears to be related to a lawsuit that alleges inappropriate conduct.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

Raj Indupuri, CEO, eClinical Solutions, touches on AI's transformation of pharma by streamlining clinical development processes, automating data management, accelerating cycle times, and improving decision-making across trials.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.

The move could signal a potential partnership between Eli Lilly and TrumpRx.

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

Join us for a premium webinar on November 4, 2025!

The change was driven by strong sales of Skyrizi and Rinvoq, and showcases robust growth and innovation in its portfolio.

Five key takeaways from the Future Investment Initiative panel on the Gulf region’s growing role in global VC.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership with Walmart to launch retail pickup for its direct-to-consumer Zepbound program, and the FDA’s new draft guidance aimed at streamlining biosimilar development.

Texas filed its lawsuit just days before Kennedy made his remarks.